These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 3123390)

  • 1. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens.
    Murphy JW; Mosley RL; Cherniak R; Reyes GH; Kozel TR; Reiss E
    Infect Immun; 1988 Feb; 56(2):424-31. PubMed ID: 3123390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes.
    Muth SM; Murphy JW
    Infect Immun; 1995 May; 63(5):1645-51. PubMed ID: 7729868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen.
    Dong ZM; Murphy JW
    Infect Immun; 1993 Dec; 61(12):5067-77. PubMed ID: 8225584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s).
    Khakpour FR; Murphy JW
    Infect Immun; 1987 Jul; 55(7):1657-62. PubMed ID: 2954914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoadsorption of Cryptococcus-specific suppressor T-cell factors.
    Mosley RL; Murphy JW; Cox RA
    Infect Immun; 1986 Mar; 51(3):844-50. PubMed ID: 2936685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and purification of antigenic components of Cryptococcus.
    Wozniak KL; Levitz SM
    Methods Mol Biol; 2009; 470():71-83. PubMed ID: 19089377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
    van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
    Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice.
    Mandel MA; Grace GG; Orsborn KI; Schafer F; Murphy JW; Orbach MJ; Galgiani JN
    Infect Immun; 2000 Nov; 68(11):6196-201. PubMed ID: 11035725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
    Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cryptococcal antigens on cell-mediated immunity.
    Murphy JW
    Rev Infect Dis; 1988; 10 Suppl 2():S432-5. PubMed ID: 2973118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans.
    Murphy JW; Schafer F; Casadevall A; Adesina A
    Infect Immun; 1998 Jun; 66(6):2632-9. PubMed ID: 9596727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunity in a cutaneous model of cryptococcosis.
    Domer JE; Lyon FL; Murphy JW
    Infect Immun; 1983 Jun; 40(3):1052-9. PubMed ID: 6343238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.
    Jesus MD; Nicola AM; Chow SK; Lee IR; Nong S; Specht CA; Levitz SM; Casadevall A
    Virulence; 2010; 1(6):500-8. PubMed ID: 21178496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
    Eckert TF; Kozel TR
    Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response.
    Fidel PL; Murphy JW
    Infect Immun; 1990 Feb; 58(2):393-8. PubMed ID: 2105273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional testing and chemical composition of cryptococcal extracts.
    Hall NK; Maluf KC; Blackstock R
    Sabouraudia; 1984; 22(5):439-42. PubMed ID: 6390739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis.
    Murphy JW; Pahlavan N
    Infect Immun; 1979 Jul; 25(1):284-92. PubMed ID: 383616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
    Blackstock R; Casadevall A
    Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.
    Buchanan KL; Murphy JW
    Infect Immun; 1993 Jul; 61(7):2854-65. PubMed ID: 8514388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of Cryptococcus neoformans from immunologically suppressed mice.
    Murphy JW
    Infect Immun; 1989 Jul; 57(7):1946-52. PubMed ID: 2499541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.